Name: Latest research reports of Ipca Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Motilal Oswal

Ipca Laboratories Ltd.

NSE: IPCALAB | BSE: 524494 | ISIN: INE571A01038 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

1491.6000 -3.50 (-0.23%)

NSE Feb 17, 2026 15:31 PM

27.68% Gain from 52W Low

Volume: 287.9K

Ipca Laboratories Ltd.

14 Oct 2024

1491.60

-0.23%

At an inflexion point

Buy: Ipca Laboratories Ltd.

Recommendation Target

Motilal Oswal

After three years of earnings deterioration, IPCA is well-poised to deliver strong earnings growth over FY24-27.

Number of FII/FPI investors decreased from 254 to 248 in Dec 2025 qtr